^
Association details:
| Biomarker: | FGF3 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | dovitinib (TKI258) (FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Excerpt:
Four patients had FGF3 amplification as measured by qPCR, with tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively.
DOI:
10.1158/1078-0432.CCR-13-0190
Trial ID:
